Influvac Sub-Unit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified surface proteins—primarily hemagglutinin and neuraminidase—from selected influenza A and B strains. After injection, these proteins are recognized by the immune system, prompting antigen‑presenting cells to activate B‑cells and T‑cells. This leads to the production of strain‑specific antibodies that neutralize the virus, providing active immunity against future exposure.

The dosing regimen for Influvac Sub-Unit is determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. Typically, a single intramuscular or subcutaneous injection is given each influenza season, but the exact volume and schedule are set by the prescriber.

Data on the use of subunit influenza vaccines during pregnancy are limited, but they are generally considered when the potential benefits outweigh any theoretical risks. Breastfeeding mothers may also receive the vaccine. Healthcare providers should evaluate individual circumstances and discuss any concerns with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. The sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details—including cold‑chain handling where required—and import documentation.

Influvac Sub-Unit is a subunit vaccine that contains only purified viral proteins, whereas split‑virus or whole‑virus vaccines include additional viral components. Subunit vaccines often have a lower reactogenicity profile, resulting in fewer local reactions, but they may require adjuvants to enhance immune response. Efficacy against matched strains is comparable when administered according to guidelines.

The vaccine must be stored at 2‑8 °C in a refrigerator, protected from light, and must never be frozen or shaken. It should be kept in the original packaging until use to maintain potency. During transport, a validated cold‑chain system is required to keep the product within the recommended temperature range.

Influvac Sub-Unit is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. The injection site should be cleaned with an antiseptic, and the dose is delivered using a sterile needle and syringe following standard aseptic technique.

The most serious adverse events include anaphylactic reactions, which require immediate medical intervention, and rare neurological conditions such as Guillain‑Barré syndrome. Patients should be observed for at least 15 minutes post‑vaccination and instructed to seek urgent care if they experience difficulty breathing, swelling of the face or throat, or rapidly progressing weakness.

Individuals with a known severe allergy to any component of the vaccine, including egg protein if present, should not receive Influvac Sub-Unit. Those who have experienced a previous severe reaction to a similar influenza subunit vaccine should also avoid it. Pregnant or breastfeeding women should consult their healthcare provider to weigh benefits against potential risks.